Application of recombinant and non-recombinant peptides in the determination of tumor response to cancer therapy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 2, 2011, Pages 320-335

  Lopez Barcons, Lluis A ^a   Ali, Arif N ^a   Diaz, Roberto ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Early prediction; Monitor response; Noninvasive imaging; Recombinant peptide; Response assessment; Tumor response

Indexed keywords

BIOLOGICAL MARKER; CAMPTOTHECIN; CASPASE; DASATINIB; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; METALLOPROTEINASE; PACLITAXEL; PEPTIDE; PHOSPHOLIPID; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER THERAPY; COLON CARCINOMA; ECHOGRAPHY; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; LUNG CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; PROTEIN LOCALIZATION; SKIN CARCINOMA; TREATMENT RESPONSE;

EID: 79551631052     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794295666     Document Type: Article

References (84)

1. Carlson, R. O. New tubulin targeting agents currently in clinical development. Expert Opin. Investig. Drugs, 2008, 17(5), 707-722.
2. Veeravagu, A.; Hsu, A. R.; Cai, W.; Hou, L. C.; Tse, V. C.; Chen, X. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent. Pat. Anticancer Drug Discov., 2007, 2(1), 59-71.
3. Sloan, B.; Scheinfeld, N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs, 2008, 9(12), 1324-1335.
4. Dinarello, C. A. Anti-inflammatory agents: present and future. Cell, 2010, 140(6), 935-950.
5. McDermott, U.; Settleman, J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J. Clin. Oncol., 2009, 27(33), 5650-5659.
6. McDermott, U.; Sharma, S. V.; Dowell, L.; Greninger, P.; Montagut, C.; Lamb, J.; Archibald, H.; Raudales, R.; Tam, A.; Lee, D.; Rothenberg, S. M.; Supko, J. G.; Sordella, R.; Ulkus, L. E.; Iafrate, A. J.; Maheswaran, S.; Njauw, C. N.; Tsao, H.; Drew, L.; Hanke, J. H.; Ma, X. J.; Erlander, M. G.; Gray, N. S.; Haber, D. A.; Settleman, J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl. Acad. Sci. USA, 2007, 104(50), 19936-19941.
7. Miller, A. B.; Hoogstraten, B.; Staquet, M.; Winkler, A. Reporting results of cancer treatment. Cancer, 1981, 47(1), 207-214.
8. Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A. T.; Christian, M. C.; Gwyther, S. G. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J. Natl. Cancer Inst., 2000, 92(3), 205-216.
9. Hodgson, D. R.; Whittaker, R. D.; Herath, A.; Amakye, D.; Clack, G. Biomarkers in oncology drug development. Mol. Oncol., 2009, 3(1), 24-32.
10. van Cruijsen, H.; van der Veldt, A.; Hoekman, K. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front BioSci., 2009, 14, 2248-2268.
11. Willmann, J. K.; van Bruggen, N.; Dinkelborg, L. M.; Gambhir, S. S. Molecular imaging in drug development. Nat. Rev. Drug Discov., 2008, 7(7), 591-607.
12. Plathow, C.; Weber, W. A. Tumor cell metabolism imaging. J. Nucl. Med., 2008, 49(Suppl_2), 43S-63.
13. Hicks, R. J.; Mac Manus, M. P.; Matthews, J. P.; Hogg, A.; Binns, D.; Rischin, D.; Ball, D. L.; Peters, L. J. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: Inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int. J. Radiat. Oncol. Biol. Phys., 2004, 60(2), 412-418.
14. Weber, W. A.; Ott, K.; Becker, K.; Dittler, H.-J.; Helmberger, H.; Avril, N. E.; Meisetschlager, G.; Busch, R.; Siewert, J.-R.; Schwaiger, M.; Fink, U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol., 2001, 19(12), 3058-3065.
15. Adessi, C.; Soto, C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem., 2002, 9(9), 963-978.
16. Antosova, Z.; Mackova, M.; Kral, V.; Macek, T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol., 2009, 27(11), 628-635.
17. Van Regenmortel, M. H. Antigenicity and immunogenicity of synthetic peptides. Biologicals, 2001, 29(3-4), 209-213.
18. Humphrey, M. J.; Ringrose, P. S. Peptides and related drugs: a review of their absorption, metabolism, and excretion. Drug Metab. Rev., 1986, 17(3-4), 283-310.
19. Shadidi, M.; Sioud, M. Selective targeting of cancer cells using synthetic peptides. Drug Resist. Updat., 2003, 6(6), 363-371.
20. Sabatino, G.; Papini, A. M. Advances in automatic, manual and microwave-assisted solid-phase peptide synthesis. Curr. Opin. Drug Discov. Devel., 2008, 11(6), 762-770.
21. Metlitskaia, L.; Cabralda, J. E.; Suleman, D.; Kerry, C.; Brinkman, J.; Bartfeld, D.; Guarna, M. M. Recombinant antimicrobial peptides efficiently produced using novel cloning and purification processes. Biotechnol. Appl. Biochem., 2004, 39(Pt 3), 339-345.
22. Winkler, D. F.; Hilpert, K.; Brandt, O.; Hancock, R. E. Synthesis of peptide arrays using SPOT-technology and the CelluSpots-method. Methods Mol. Biol., 2009, 570, 157-174.
23. Shrivastava, A.; Nunn, A. D.; Tweedle, M. F. Designer peptides: learning from nature. Curr. Pharm. Des., 2009, 15(6), 675-681.
24. Shrivastava, A.; von Wronski, M. A.; Sato, A. K.; Dransfield, D. T.; Sexton, D.; Bogdan, N.; Pillai, R.; Nanjappan, P.; Song, B.; Marinelli, E.; DeOliveira, D.; Luneau, C.; Devlin, M.; Muruganandam, A.; Abujoub, A.; Connelly, G.; Wu, Q. L.; Conley, G.; Chang, Q.; Tweedle, M. F.; Ladner, R. C.; Swenson, R. E.; Nunn, A. D. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng. Des. Sel., 2005, 18(9), 417-424.
25. Jaffe, C. C. Measures of response: RECIST, WHO, and new alternatives. J. Clin. Oncol., 2006, 24(20), 3245-3251.
26. Therasse, P.; Eisenhauer, E. A.; Verweij, J. RECIST revisited: A review of validation studies on tumour assessment. Eur. J. Cancer, 2006, 42(8), 1031-1039.
27. Blankenberg, F. G.; Storrs, R. W.; Naumovski, L.; Goralski, T.; Spielman, D. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood, 1996, 87(5), 1951-1956.
28. Brisdelli, F.; Iorio, E.; Knijn, A.; Ferretti, A.; Marcheggiani, D.; Lenti, L.; Strom, R.; Podo, F.; Bozzi, A. Two-step formation of 1H NMR visible mobile lipids during apoptosis of paclitaxel-treated K562 cells. Biochem. Pharmacol., 2003, 65(8), 1271-1280.
29. Gossmann, A.; Helbich, T. H.; Kuriyama, N.; Ostrowitzki, S.; Roberts, T. P.; Shames, D. M.; van Bruggen, N.; Wendland, M. F.; Israel, M. A.; Brasch, R. C. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to antiangiogenic therapy in a xenograft model of glioblastoma multiforme. J. Magn. Reson. Imaging, 2002, 15(3), 233-240.
30. Roth, Y.; Tichler, T.; Kostenich, G.; Ruiz-Cabello, J.; Maier, S. E.; Cohen, J. S.; Orenstein, A.; Mardor, Y. High-b-value diffusionweighted mr imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice1. Radiology, 2004, 232(3), 685-692.
31. Mikhaeel, N. G.; Hutchings, M.; Fields, P. A.; O'Doherty, M. J.; Timothy, A. R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann. Oncol., 2005, 16(9), 1514-1523.
32. Belhocine, T.; Steinmetz, N.; Hustinx, R.; Bartsch, P.; Jerusalem, G.; Seidel, L.; Rigo, P.; Green, A. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human annexin v in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res., 2002, 8(9), 2766-2774.
33. Del Vecchio, S.; Zannetti, A.; Ciarmiello, A.; Aloj, L.; Caraco, C.; Fonti, R.; Botti, G.; D'Aiuto, G.; Salvatore, M. Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29(6), 809-814.
34. Haas, R. L.; de Jong, D.; Valdes Olmos, R. A.; Hoefnagel, C. A.; van den Heuvel, I.; Zerp, S. F.; Bartelink, H.; Verheij, M. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int. J. Radiat. Oncol. Biol. Phys., 2004, 59(3), 782-787.
35. Lahorte, C. M.; Vanderheyden, J. L.; Steinmetz, N.; Van de Wiele, C.; Dierckx, R. A.; Slegers, G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(6), 887-919.
36. Van de Wiele, C.; Lahorte, C.; Vermeersch, H.; Loose, D.; Mervillie, K.; Steinmetz, N. D.; Vanderheyden, J.-L.; Cuvelier, C. A.; Slegers, G.; Dierck, R. A. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J. Clin. Oncol., 2003, 21(18), 3483-3487.
37. Beer, A. J.; Niemeyer, M.; Carlsen, J.; Sarbia, M.; Nahrig, J.; Watzlowik, P.; Wester, H. J.; Harbeck, N.; Schwaiger, M. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J. Nucl. Med., 2008, 49(2), 255-259.
38. Morrison, M. S.; Ricketts, S. A.; Barnett, J.; Cuthbertson, A.; Tessier, J.; Wedge, S. R. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J. Nucl. Med., 2009, 50(1), 116-122.
39. Haubner, R.; Decristoforo, C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci., 2009, 14, 872-886.
40. Liu, S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug. Chem., 2009, 20(12), 2199-2213.
41. Kenny, L. M.; Coombes, R. C.; Oulie, I.; Contractor, K. B.; Miller, M.; Spinks, T. J.; McParland, B.; Cohen, P. S.; Hui, A. M.; Palmieri, C.; Osman, S.; Glaser, M.; Turton, D.; Al-Nahhas, A.; Aboagye, E. O. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J. Nucl. Med., 2008, 49(6), 879-886.
42. Arap, M. A. Phage display technology - Applications and innovations. Genet. Mol. Biol., 2005, 28(1), 1-9.
43. Jaboin, J. J.; Han, Z.; Hallahan, D. E. Using in vivo biopanning for the development of radiation-guided drug delivery systems. Methods Mol. Biol., 2009, 542, 285-300.
44. Hallahan, D.; Geng, L.; Qu, S. M.; Scarfone, C.; Giorgio, T.; Donnelly, E.; Gao, X.; Clanton, J. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell, 2003, 3(1), 63-74.
45. Hallahan, D. E.; Geng, L.; Cmelak, A. J.; Chakravarthy, A. B.; Martin, W.; Scarfone, C.; Gonzalez, A. Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature. J. Control Release, 2001, 74(1-3), 183-191.
46. Hallahan, D. E.; Qu, S.; Geng, L.; Cmelak, A.; Chakravarthy, A.; Martin, W.; Scarfone, C.; Giorgio, T. Radiation-mediated control of drug delivery. Am. J. Clin. Oncol., 2001, 24(5), 473-480.
47. Hallahan, D. E.; Staba-Hogan, M. J.; Virudachalam, S.; Kolchinsky, A. X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res., 1998, 58(22), 5216-5220.
48. Passarella, R. J.; Spratt, D. E.; van der Ende, A. E.; Phillips, J. G.; Wu, H.; Sathiyakumar, V.; Zhou, L.; Hallahan, D. E.; Harth, E.; Diaz, R. Targeted nanoparticles that deliver a sustained, specific release of paclitaxel to irradiated tumors. Cancer Res., 2010, 70(11), 4550-4559.
49. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279(5349), 377-380.
50. Dudek, J.; Benedix, J.; Cappel, S.; Greiner, M.; Jalal, C.; Muller, L.; Zimmermann, R. Functions and pathologies of BiP and its interaction partners. Cell Mol. Life Sci., 2009, 66(9), 1556-1569.
51. Han, Z.; Fu, A.; Wang, H.; Diaz, R.; Geng, L.; Onishko, H.; Hallahan, D. E. Noninvasive assessment of cancer response to therapy. Nat. Med., 2008, 14(3), 343-349.
52. Medarova, Z.; Pham, W.; Kim, Y.; Dai, G.; Moore, A. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int. J. Cancer, 2006, 118(11), 2796-2802.
53. Medarova, Z.; Rashkovetsky, L.; Pantazopoulos, P.; Moore, A. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res., 2009, 69(3), 1182-1189.
54. Thapa, N.; Kim, S.; So, I. S.; Lee, B. H.; Kwon, I. C.; Choi, K.; Kim, I. S. Discovery of a phosphatidylserine-recognizing peptide and its utility in molecular imaging of tumour apoptosis. J. Cell Mol. Med., 2008, 12(5A), 1649-1660.
55. Dumont, R. A.; Hildebrandt, I.; Su, H.; Haubner, R.; Reischl, G.; Czernin, J. G.; Mischel, P. S.; Weber, W. A. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res., 2009, 69(7), 3173-3179.
56. Jung, K. H.; Lee, K. H.; Paik, J. Y.; Ko, B. H.; Bae, J. S.; Lee, B. C.; Sung, H. J.; Kim, D. H.; Choe, Y. S.; Chi, D. Y. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J. Nucl. Med., 2006, 47(12), 2000-2007.
57. Bullok, K. E.; Maxwell, D.; Kesarwala, A. H.; Gammon, S.; Prior, J. L.; Snow, M.; Stanley, S.; Piwnica-Worms, D. Biochemical and in vivo characterization of a small, membrane-permeant, caspaseactivatable far-red fluorescent peptide for imaging apoptosis. Biochemistry, 2007, 46(13), 4055-4065.
58. Passarella, R. J.; Zhou, L.; Phillips, J. G.; Wu, H.; Hallahan, D. E.; Diaz, R. Recombinant peptides as biomarkers for tumor response to molecular targeted therapy. Clin. Cancer Res., 2009, 15(20), 6421-6429.
59. Palmowski, M.; Huppert, J.; Ladewig, G.; Hauff, P.; Reinhardt, M.; Mueller, M. M.; Woenne, E. C.; Jenne, J. W.; Maurer, M.; Kauffmann, G. W.; Semmler, W.; Kiessling, F. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects. Mol. Cancer Ther., 2008, 7(1), 101-109.
60. Milano, V.; Piao, Y.; LaFortune, T.; de Groot, J. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol. Cancer Ther., 2009, 8(2), 394-406.
61. Fomchenko, E. I.; Holland, E. C. Platelet-derived growth factormediated gliomagenesis and brain tumor recruitment. Neurosurg. Clin. N. Am., 2007, 18(1), 39-58, viii.
62. Homsi, J.; Cubitt, C.; Daud, A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin. Ther. Targets, 2007, 11(1), 91-100.
63. Ding, Q.; Stewart, J., Jr.; Olman, M. A.; Klobe, M. R.; Gladson, C. L. The pattern of enhancement of Src kinase activity on plateletderived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J. Biol. Chem., 2003, 278(41), 39882-39891.
64. Haubner, R.; Weber, W. A.; Beer, A. J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K. F.; Goebel, M.; Hein, R.; Wester, H. J.; Kessler, H.; Schwaiger, M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med., 2005, 2(3), e70.
65. Haubner, R.; Wester, H. J.; Weber, W. A.; Mang, C.; Ziegler, S. I.; Goodman, S. L.; Senekowitsch-Schmidtke, R.; Kessler, H.; Schwaiger, M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res., 2001, 61(5), 1781-1785.
66. Janssen, M.; Oyen, W. J.; Massuger, L. F.; Frielink, C.; Dijkgraaf, I.; Edwards, D. S.; Radjopadhye, M.; Corstens, F. H.; Boerman, O. C. Comparison of a monomeric and dimeric radiolabeled RGDpeptide for tumor targeting. Cancer Biother. Radiopharm., 2002, 17(6), 641-646.
67. Klibanov, A. L. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest. Radiol., 2006, 41(3), 354-362.
68. Lindner, J. R. Microbubbles in medical imaging: current applications and future directions. Nat. Rev. Drug Discov., 2004, 3(6), 527-532.
69. Yun, Z.; Menter, D. G.; Nicolson, G. L. Involvement of integrin alphavbeta3 in cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma. Cancer Res., 1996, 56(13), 3103-3111.
70. Cheng, Y. F.; Kramer, R. H. Human microvascular endothelial cells express integrin-related complexes that mediate adhesion to the extracellular matrix. J. Cell Physiol., 1989, 139(2), 275-286.
71. Conforti, G.; Zanetti, A.; Colella, S.; Abbadini, M.; Marchisio, P. C.; Pytela, R.; Giancotti, F.; Tarone, G.; Languino, L. R.; Dejana, E. Interaction of fibronectin with cultured human endothelial cells: characterization of the specific receptor. Blood, 1989, 73(6), 1576-1585.
72. Grant, D. S.; Tashiro, K.; Segui-Real, B.; Yamada, Y.; Martin, G. R.; Kleinman, H. K. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell, 1989, 58(5), 933-943.
73. Nagata, S. Apoptotic DNA fragmentation. Exp. Cell Res., 2000, 256(1), 12-18.
74. Li, M. O.; Sarkisian, M. R.; Mehal, W. Z.; Rakic, P.; Flavell, R. A. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science, 2003, 302(5650), 1560-1563.
75. Kurokawa, M.; Kornbluth, S. Caspases and kinases in a death grip. Cell, 2009, 138(5), 838-854.
76. Lien, S.; Pastor, R.; Sutherlin, D.; Lowman, H. B. A substratephage approach for investigating caspase specificity. Protein J., 2004, 23(6), 413-425.
77. Bullok, K.; Piwnica-Worms, D. Synthesis and characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. J. Med. Chem., 2005, 48(17), 5404-5407.
78. Moore, A.; Medarova, Z.; Potthast, A.; Dai, G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res., 2004, 64(5), 1821-1827.
79. Perey, L.; Hayes, D. F.; Maimonis, P.; Abe, M.; O'Hara, C.; Kufe, D. W. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res., 1992, 52(9), 2563-2568.
80. Singh, R.; Bandyopadhyay, D. MUC1: a target molecule for cancer therapy. Cancer Biol. Ther., 2007, 6(4), 481-486.
81. Dorn, D. C.; Harnack, U.; Pecher, G. Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2. Anticancer Res., 2004, 24(2B), 821-825.
82. Daniel, V. C.; Marchionni, L.; Hierman, J. S.; Rhodes, J. T.; Devereux, W. L.; Rudin, C. M.; Yung, R.; Parmigiani, G.; Dorsch, M.; Peacock, C. D.; Watkins, D. N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res., 2009, 69(8), 3364-3373.
83. De Witt Hamer, P. C.; Van Tilborg, A. A.; Eijk, P. P.; Sminia, P.; Troost, D.; Van Noorden, C. J.; Ylstra, B.; Leenstra, S. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene, 2008, 27(14), 2091-2096.
84. Pandita, A.; Aldape, K. D.; Zadeh, G.; Guha, A.; James, C. D. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer, 2004, 39(1), 29-36.